Platelet-Rich Protein and the Endometrium
Not Applicable
- Conditions
- Infertility
- Registration Number
- NCT02973555
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
Platelet-rich plasma (PRP) may promote the endometrial growth and improve pregnancy outcome of patients with thin endometrium undergoing ART treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
- Women undergoing a frozen thawed embryo transfer cycle with poor endometrial response to estrogen (< 7 mm) after at least two standard preparation protocols, of which one was canceled due to thin endometrium
Exclusion Criteria
- none
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method endometrial thickness >7mm 1 month
- Secondary Outcome Measures
Name Time Method Positive serum pregnancy test 14 days post embryo transfer
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does PRP utilize to stimulate endometrial growth in infertile patients with thin endometrium?
How does PRP injection compare to standard hormonal therapies in improving pregnancy outcomes for thin endometrium patients undergoing ART?
Are there specific endometrial biomarkers that predict response to PRP treatment in assisted reproductive technology?
What are the potential adverse events associated with PRP administration in patients with infertility undergoing ART?
What combination therapies involving PRP are being explored to enhance endometrial receptivity and pregnancy success in thin endometrium cases?
Trial Locations
- Locations (1)
Hadassah Medical Organization
🇮🇱Jerusalem, Israel
Hadassah Medical Organization🇮🇱Jerusalem, Israel